Albumin administration prevents @entity16 and death in a @entity19 model of severe @entity4837 XXXX .

@entity4837 @entity19 @entity648 @entity16 @entity30440 @entity3638 @entity2359
Therapies to prevent severe @entity4837 unconjugated @entity3638 and kernicterus are phototherapy and, in unresponsive cases, exchange transfusion, which has significant morbidity and mortality risks. @entity2359 is caused by the fraction of unconjugated @entity648 not bound to albumin (free @entity648 , Bf). Human serum albumin (HSA) administration was suggested to increase plasma @entity648 -binding capacity. However, its clinical use is infrequent due to difficulties to address its potential preventive and curative benefits, and to the absence of reliable markers to monitor @entity648 @entity2359 risk. We used a genetic @entity19 model of unconjugated @entity3638 showing severe @entity16 and @entity30440 . We treated mutant pups with repeated HSA administration since birth, without phototherapy application. Daily intraperitoneal HSA administration completely rescued @entity16 and lethality, depending on dosage and administration frequency. Albumin infusion increased plasma @entity648 -binding capacity, mobilizing @entity648 from tissues to plasma. This resulted in reduced plasma Bf, forebrain and cerebellum @entity648 levels. We showed that, in our experimental model, Bf is the best marker to determine the risk of developing @entity16 . These results support the potential use of albumin administration in severe acute @entity3638 conditions to prevent or treat @entity648 @entity2359 in situations in which exchange transfusion may be required.
